Global innovation firm Plug and Play to partner with Cleveland Clinic, JumpStart on health innovation

Silicon Valley company plugs into Cleveland

A renowned Silicon Valley innovation company is coming to Cleveland to help create an accelerator focused on biotech and digital health innovation and attract companies and startups from around the world.

3rd Annual Cleveland Medical Hackathon to Take on Population Health, Precision Medicine, Public Health, and the Opioid Crisis

This fall, the 3rd Annual Cleveland Medical Hackathon will once again deliver an innovative jolt to the healthcare industry. Students, doctors, nurses, public health officials, developers, designers, engineers, researchers, and community members will gather at the Global Center for Health Innovation October 21 - 22 for a high-energy, all-night, problem-solving session.

ClearFlow, Inc. Announces Positive US Clinical Trial Results

ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that positive clinical trial results were presented at the International Coronary Congress (ICC) 2017 annual meeting on August 18th, 2017 in New York City, NY. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Retained Blood and ICU Resources after Off-Pump Coronary Artery Bypass Surgery.”

Intellirod Spine™ Acquires Cleveland Clinic IP

Intellirod Spine, the spinal implant company developing disposable and implantable wireless RFID sensor technology for monitoring spinal rod strains, secured additional equity financing from new and existing investors led by the OhioHealth Innovation Development Fund and Queen City Angel First Fund V. Funds will be used to reach key milestones toward the commercialization of the company’s sensor technologies and related lumbar fusion implants.

OncoSynergy and Infuseon Therapeutics Partner to Combat Glioblastoma

Infuseon Therapeutics and OncoSynergy have entered into a strategic alliance to test an investigational glioblastoma therapeutic, OS2966, in combination with a novel delivery device, the Cleveland Multiport CatheterTM. Glioblastoma is the most common and malignant primary brain tumor. Despite a median survival of merely 12 months, there have been only four FDA approved therapies and no improvement in overall survival in nearly three decades. This unmet need is driven in part by the inability of most chemotherapies and particularly biologics to penetrate the blood-brain-barrier.

ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that the United States Food & Drug Administration (FDA) has granted 510[k] clearance for the company’s proprietary FlowGlide™ Active Clearance Technology® System.

The FlowGlide™ System is the next generation of ClearFlow’s Active Clearance Technology that prevents or reduces chest drains from occluding with clot, which can lead to retained blood around the heart and lungs. The composite of drainage-related complications that are detrimental to outcomes after cardiothoracic surgery and that may require early or late intervention to remediate is known as Retained Blood Syndrome (RBS). These clinical complications have significant economic consequences, including higher costs of care for patients, hospitals, and society at large.

Infuseon Therapeutics’ Cleveland Multiport CatheterTM (CMC), a multiport convection-enhanced delivery catheter, was designed by neurosurgeon Michael Vogelbaum, MD, PhD, from Cleveland Clinic’s Brain Tumor and NeuroOncology Center and Department of Neurosurgery, to effectively deliver therapeutics to patients at the site of their disease. FDA clearance was granted in March 2017.